SCHEMBL6542828

SCHEMBL6542828

O=C(O)c1cc(CNc2ncccc2C(=O)Nc2cc3ccccc3cn2)ccn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 17/20 0.49
MEN1 O00255 2/20 0.43
MAPT P10636 2/20 0.43
KMT2A Q03164 2/20 0.43
KDM4E B2RXH2 1/20 0.43
LMNA P02545 1/20 0.43
GLA P06280 1/20 0.43
HTT P42858 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
WNT3A P56704 1/20 0.42
CIT O14578 1/20 0.42
MAP3K7 O43318 1/20 0.42
RIPK2 O43353 1/20 0.42
STK10 O94804 1/20 0.42
MAP4K4 O95819 1/20 0.42
ABL1 P00519 1/20 0.42
EGFR P00533 1/20 0.42
RAF1 P04049 1/20 0.42
LCK P06239 1/20 0.42
FYN P06241 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6543388 0.91 KIT (0.48) KDRWNT3ACITMAP3K7RIPK2
SCHEMBL4036764 0.88 FLT1 (0.51) KDRKDM4EKITBRAFFLT1
SCHEMBL6542520 0.88 ANO1 (0.48) KDRCITMAP3K7RIPK2STK10
SCHEMBL446890 0.87 KDR (0.63) KDRWNT3ACITMAP3K7RIPK2
SCHEMBL6542861 0.85 KIT (0.49) KDRCITMAP3K7RIPK2STK10
SCHEMBL1490923 0.85 KIT (0.51) KDRCITMAP3K7RIPK2STK10
SCHEMBL6543102 0.82 KDR (0.45) KDRMEN1MAPTKMT2AKDM4E
SCHEMBL3119364 0.80 KDR (0.45) KDRMEN1MAPTKMT2AKDM4E
SCHEMBL3873679 0.79 KIT (0.61) KDRKITBRAFFLT1
SCHEMBL6542940 0.79 CHEK1 (0.50) KDRWNT3ARETMAP3K20RIPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040254185-A1 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254185-A1 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 FLT4, KDR, FLT1 KDR 2/4885MEN1 3913/4885MAPT 3362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.